期刊
ACS CENTRAL SCIENCE
卷 7, 期 2, 页码 365-378出版社
AMER CHEMICAL SOC
DOI: 10.1021/acscentsci.0c01670
关键词
-
资金
- MIT
- National Science Foundation (NSF) CAREER Award [CHE-1351807]
- Koch Institute
- Dana-Farber/Harvard Cancer Center
- National Institutes of Health Postdoctoral Fellowship [F32-CA239362]
- NERCE [U54-AI057159]
- National Cancer Institute [P30-CA14051]
- Damon Runyon Cancer Research Foundation Innovation Award
Novel immunotoxins were developed by linking full-length IgG antibodies with nontoxic anthrax proteins, showing efficient and potent activity against malignant cells with high specificity for HER2 and EGFR, as well as increased pharmacokinetics and in vivo safety, suggesting promise for further therapeutic development.
Therapeutic immunotoxins composed of antibodies and bacterial toxins provide potent activity against malignant cells, but joining them with a defined covalent bond while maintaining the desired function is challenging. Here, we develop novel immunotoxins by dovetailing full-length immunoglobulin G (IgG) antibodies and nontoxic anthrax proteins, in which the C terminus of the IgG heavy chain is connected to the side chain of anthrax toxin protective antigen. This strategy enabled efficient conjugation of protective antigen variants to trastuzumab (Tmab) and cetuximab (Cmab) antibodies. The conjugates effectively perform intracellular delivery of edema factor and N terminus of lethal factor (LFN) fused with diphtheria toxin and Ras/Rap1-specific endopeptidase. Each conjugate shows high specificity for cells expressing human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), respectively, and potent activity across six Tmab- and Cmab-resistant cell lines. The conjugates also exhibit increased pharmacokinetics and pronounced in vivo safety, which shows promise for further therapeutic development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据